BIND

BIND Therapeutics, Inc. Press Releases

$6.79
*  
0.23
3.28%
Get BIND Alerts
*Delayed - data as of Nov. 25, 2014  -  Find a broker to begin trading BIND now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3W Dosing Schedule for Patients with Non-small Cell Lung Cancer at 26th EORTC-NCI-AACR Annual Symposium
11/19/2014 7:00:00 AM - Business Wire


Flagship VentureLabs™ Introduces Symbiota, Pioneer of Agricultural Innovation Through the Plant Microbiome
11/13/2014 8:30:00 AM - PR Newswire


BIND Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update
11/6/2014 7:30:00 AM - Business Wire
▼-20.58 % Price Change since this news event. The Volume Ratio is 3.3.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin™ Nanomedicines for Oncology
11/6/2014 7:25:00 AM - Business Wire
▼-20.58 % Price Change since this news event. The Volume Ratio is 3.3.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BIND Therapeutics Appoints Hagop Youssoufian, M.Sc., M.D. as Chief Medical Officer
11/4/2014 8:30:00 AM - Business Wire
▼-15.13 % Price Change since this news event. The Volume Ratio is 1.25.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BIND Therapeutics Announces Availability of Abstract with Preliminary Data from Phase 2 Study of BIND-014 in Non-small Cell Lung Cancer
10/30/2014 8:30:00 AM - Business Wire
▼-13.28 % Price Change since this news event. The Volume Ratio is 9.15.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Cartier Drills the Massive Sulphides (Zn-Cu-Ag) on the MacCormack Property
10/30/2014 8:30:00 AM - Market Wire


BIND Therapeutics to Present at November Healthcare Conferences
10/29/2014 8:30:00 AM - Business Wire
▼-12.84 % Price Change since this news event. The Volume Ratio is 5.91.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BIND Therapeutics to Report Third Quarter 2014 Financial Results on November 6, 2014
10/23/2014 8:30:00 AM - Business Wire
▼-12.95 % Price Change since this news event. The Volume Ratio is 2.44.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


BIND Therapeutics Appoints Two New Board Members
9/3/2014 8:30:00 AM - Business Wire